Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
885 Leser
Artikel bewerten:
(2)

Delisting of Securities of Genesis Growth Tech Acquisition Corp.; Financial Strategies Acquisition Corp.; Kiromic BioPharma, Inc.; Infinity Pharmaceuticals, Inc.; Molekule Group, Inc.; EBET, Inc.; Shift Technologies, Inc.; Ontrak, Inc.; RVL Pharmaceutical

Finanznachrichten News

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition Corp. Genesis Growth Tech Acquisition Corp.'s securities were suspended on July 25, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Financial Strategies Acquisition Corp. Financial Strategies Acquisition Corp.'s securities were suspended on August 31, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Kiromic BioPharma, Inc. Kiromic BioPharma, Inc.'s securities were suspended on September 14, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.'s securities were suspended on September 14, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Molekule Group, Inc. Molekule Group, Inc.'s securities were suspended on October 13, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of EBET, Inc. EBET, Inc.'s securities were suspended on October 13, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Shift Technologies, Inc. Shift Technologies, Inc.'s securities were suspended on October 19, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the preferred stock of Ontrak, Inc. Ontrak, Inc.'s securities were suspended on October 20, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of RVL Pharmaceuticals plc. RVL Pharmaceuticals plc's securities were suspended on October 23, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Biocept, Inc. Biocept, Inc.'s securities were suspended on October 25, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Akumin Inc. Akumin Inc.'s securities were suspended on October 26, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Appreciate Holdings, Inc. Appreciate Holdings, Inc.'s securities were suspended on October 27, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Liberty TripAdvisor Holdings, Inc. Liberty TripAdvisor Holdings, Inc.'s securities were suspended on October 30, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Tempo Automation Holdings, Inc. Tempo Automation Holdings, Inc.'s securities were suspended on November 2, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Medicenna Therapeutics Corp. Medicenna Therapeutics Corp.'s securities were suspended on November 2, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of RiceBran Technologies. RiceBran Technologies's securities were suspended on November 8, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Acer Therapeutics Inc. Acer Therapeutics Inc.'s securities were suspended on November 9, 2023, and have not traded on Nasdaq since that time.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq's rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.


© 2023 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.